JP2010511381A - 神経前駆細胞又は神経幹細胞の神経細胞への分化及び増殖の誘導方法、分化及び増殖誘導用組成物、及び薬学的製剤 - Google Patents
神経前駆細胞又は神経幹細胞の神経細胞への分化及び増殖の誘導方法、分化及び増殖誘導用組成物、及び薬学的製剤 Download PDFInfo
- Publication number
- JP2010511381A JP2010511381A JP2009539185A JP2009539185A JP2010511381A JP 2010511381 A JP2010511381 A JP 2010511381A JP 2009539185 A JP2009539185 A JP 2009539185A JP 2009539185 A JP2009539185 A JP 2009539185A JP 2010511381 A JP2010511381 A JP 2010511381A
- Authority
- JP
- Japan
- Prior art keywords
- stem cells
- cells
- neural
- disease
- mesenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001178 neural stem cell Anatomy 0.000 title claims abstract description 43
- 230000004069 differentiation Effects 0.000 title claims abstract description 28
- 210000005155 neural progenitor cell Anatomy 0.000 title claims abstract description 27
- 230000035755 proliferation Effects 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 230000001939 inductive effect Effects 0.000 title claims abstract description 16
- 210000002569 neuron Anatomy 0.000 title claims description 22
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 64
- 210000004700 fetal blood Anatomy 0.000 claims abstract description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 210000003061 neural cell Anatomy 0.000 claims abstract description 12
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 8
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 7
- 230000000472 traumatic effect Effects 0.000 claims abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims abstract description 6
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 6
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 6
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims abstract description 6
- 208000006011 Stroke Diseases 0.000 claims abstract description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 6
- 238000012258 culturing Methods 0.000 claims description 14
- 208000028389 Nerve injury Diseases 0.000 claims description 10
- 230000008764 nerve damage Effects 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000005779 cell damage Effects 0.000 claims description 5
- 208000037887 cell injury Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 201000010099 disease Diseases 0.000 abstract description 6
- 238000002659 cell therapy Methods 0.000 abstract description 5
- 238000002955 isolation Methods 0.000 abstract 1
- 231100000878 neurological injury Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 42
- 239000002609 medium Substances 0.000 description 9
- 238000012744 immunostaining Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 6
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 5
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000003606 umbilical vein Anatomy 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 230000004031 neuronal differentiation Effects 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/03—Coculture with; Conditioned medium produced by non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86787506P | 2006-11-30 | 2006-11-30 | |
| KR1020060120479A KR100959995B1 (ko) | 2006-12-01 | 2006-12-01 | 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물 |
| PCT/KR2007/006084 WO2008066330A1 (en) | 2006-11-30 | 2007-11-29 | Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013160426A Division JP5871865B2 (ja) | 2006-11-30 | 2013-08-01 | 神経前駆細胞又は神経幹細胞の神経細胞への分化及び増殖の誘導方法、分化及び増殖誘導用組成物、及び薬学的製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010511381A true JP2010511381A (ja) | 2010-04-15 |
| JP2010511381A5 JP2010511381A5 (enExample) | 2015-02-26 |
Family
ID=39468070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009539185A Pending JP2010511381A (ja) | 2006-11-30 | 2007-11-29 | 神経前駆細胞又は神経幹細胞の神経細胞への分化及び増殖の誘導方法、分化及び増殖誘導用組成物、及び薬学的製剤 |
| JP2013160426A Active JP5871865B2 (ja) | 2006-11-30 | 2013-08-01 | 神経前駆細胞又は神経幹細胞の神経細胞への分化及び増殖の誘導方法、分化及び増殖誘導用組成物、及び薬学的製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013160426A Active JP5871865B2 (ja) | 2006-11-30 | 2013-08-01 | 神経前駆細胞又は神経幹細胞の神経細胞への分化及び増殖の誘導方法、分化及び増殖誘導用組成物、及び薬学的製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9387226B2 (enExample) |
| EP (1) | EP2099901B1 (enExample) |
| JP (2) | JP2010511381A (enExample) |
| CN (1) | CN101541954B (enExample) |
| AU (1) | AU2007326171B2 (enExample) |
| CA (1) | CA2669304C (enExample) |
| MX (1) | MX2009005496A (enExample) |
| WO (1) | WO2008066330A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018530992A (ja) * | 2015-07-22 | 2018-10-25 | 中國醫藥大學 | 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途 |
| US10660918B2 (en) | 2015-07-22 | 2020-05-26 | China Medical University | Method for enhancing insulin like growth factor 1 receptor expression of mesenchymal stem cell, method for isolating mesenchymal stem cell, and use of mesenchymal stem cell |
| US11110129B2 (en) | 2015-07-22 | 2021-09-07 | China Medical University | Method for treating multiple sclerosis |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110050521A (ko) | 2008-08-20 | 2011-05-13 | 안트로제네시스 코포레이션 | 개선된 세포 조성물 및 그의 제조 방법 |
| CN101831401A (zh) * | 2010-04-23 | 2010-09-15 | 天津昂赛细胞基因工程有限公司 | 体外诱导间充质干细胞分化为神经干细胞的方法 |
| US11286463B2 (en) | 2012-03-08 | 2022-03-29 | Advanced ReGen Medical Technologies, LLC | Reprogramming of aged adult stem cells |
| KR20160018482A (ko) * | 2013-04-09 | 2016-02-17 | 어드밴스드 리젠 메디컬 테크놀로지스, 엘엘씨 | 세포 회복을 위한 조성물 및 그의 제조 및 사용 방법 |
| PL3083671T3 (pl) | 2013-12-20 | 2021-03-22 | Fred Hutchinson Cancer Center | Znakowane chimeryczne cząsteczki efektorowe i ich receptory |
| US10772911B2 (en) | 2013-12-20 | 2020-09-15 | Advanced ReGen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
| CR20160307A (es) | 2013-12-20 | 2016-11-08 | Advanced Regen Medical Tech Llc | Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas |
| KR101808762B1 (ko) * | 2014-10-29 | 2017-12-14 | 차의과학대학교 산학협력단 | C3 또는 C1r 보체를 분비하는 태반 유래 세포 및 이를 포함하는 조성물 |
| WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| ITUB20159750A1 (it) * | 2015-12-30 | 2017-06-30 | Alfredo Gorio | Metodo per la promozione ed il miglioramento delle proprieta? del tessuto adiposo, tessuto e cellule ottenute tramite detto metodo |
| JP7101367B2 (ja) | 2016-04-28 | 2022-07-15 | 北海道公立大学法人 札幌医科大学 | シナプス形成剤 |
| KR20180130589A (ko) | 2016-04-29 | 2018-12-07 | 어드밴스드 리젠 메디컬 테크놀로지스, 엘엘씨 | 마이크로rna 조성물 및 이의 제조 및 사용 방법 |
| EP3464565A4 (en) * | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | CELL EXPANSION |
| WO2019143847A1 (en) | 2018-01-18 | 2019-07-25 | Advanced ReGen Medical Technologies, LLC | Therapeutic compositions and methods of making and using the same |
| WO2019237106A1 (en) * | 2018-06-08 | 2019-12-12 | University Of Virginia Patent Foundation | Compositions and methods for treating stroke |
| WO2022004822A1 (ja) * | 2020-06-30 | 2022-01-06 | 国立大学法人高知大学 | 胎児付属物由来組織細胞及び／又は臍帯血細胞を培養するための海洋深層水を含む培地 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1302534A1 (en) * | 2000-06-26 | 2003-04-16 | Renomedix Institute Inc. | Cell fraction containing cells capable of differentiating into neural cells |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354588B1 (en) | 1987-05-04 | 2008-04-08 | Dana Farber Cancer Institute | Functional derivatives of ICAM-1 with altered ability to bind LFA-1 or HRV |
| US5733542A (en) | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
| US5837576A (en) | 1997-10-31 | 1998-11-17 | Vanguard International Semiconductor Corporation | Method for forming a capacitor using a silicon oxynitride etching stop layer |
| US6900299B1 (en) | 1999-03-11 | 2005-05-31 | University Of South Florida | Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection |
| CA2363269C (en) | 1999-03-12 | 2012-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Dna vaccination for treatment of autoimmune disease |
| US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
| US20040208858A1 (en) | 2000-04-12 | 2004-10-21 | Gihan Tennekoon | Therapeutic uses for mesenchymal stromal cells |
| US20040037775A1 (en) | 2000-08-01 | 2004-02-26 | Siahaan Teruna J. | Leukocyte internalized peptide-drug conjugates |
| US7560280B2 (en) | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
| KR100449141B1 (ko) | 2001-04-19 | 2004-09-21 | (주)라이프코드 | 간엽 간세포를 신경세포로 분화시키는 방법 |
| CN1281739C (zh) | 2002-02-19 | 2006-10-25 | 美迪宝斯特有限公司 | 从脐带血中分离并扩大培养间充质干细胞/祖细胞及将脐带血来源的间充质干细胞/祖细胞分化成各种间充质组织的方法 |
| US20090192105A1 (en) | 2002-02-20 | 2009-07-30 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA) |
| AU2003252559A1 (en) | 2002-08-17 | 2004-03-03 | Hae-Young Suh | A method for transdifferentiating mesenchymal stem cells into neuronal cells |
| US20040203142A1 (en) | 2003-04-14 | 2004-10-14 | Reliance Life Sciences Pvt. Ltd. | Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes |
| EP1674566B1 (en) | 2003-09-09 | 2011-04-13 | Keio University | Method of promoting subsistence and/or proliferation of neural stem cell and promoting extension of neurite, promoter therefor, pharmaceutical composition containing neural stem cell, method of assay and method of screening |
| US20060094064A1 (en) | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
| EP1767617A1 (en) | 2005-09-26 | 2007-03-28 | Letizia Mazzini | Mesenchymal stem cells isolation and expansion method and uses thereof |
| EP1951665A1 (en) | 2005-11-14 | 2008-08-06 | Dominion Pharmakine S.L. | Novel inhibitors of the lfa-1/icam-1 interaction, and uses thereof |
| US20070253931A1 (en) | 2006-01-12 | 2007-11-01 | Osiris Therapeutics, Inc. | Use of mesenchymal stem cells for treating genetic diseases and disorders |
| KR100792184B1 (ko) | 2006-05-12 | 2008-01-07 | 재단법인서울대학교산학협력재단 | 개의 제대혈, 태반 및 개 태아의 심장 유래 다분화능 성체줄기세포, 그 제조방법 및 이를 함유하는 세포 치료제 |
| KR20080049562A (ko) | 2006-11-30 | 2008-06-04 | 가톨릭대학교 산학협력단 | 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는 신경손상 질환 치료제 |
| KR20100054711A (ko) | 2008-11-14 | 2010-05-25 | 메디포스트(주) | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
-
2007
- 2007-11-29 US US12/516,913 patent/US9387226B2/en active Active
- 2007-11-29 CN CN2007800440974A patent/CN101541954B/zh active Active
- 2007-11-29 EP EP07851154.0A patent/EP2099901B1/en active Active
- 2007-11-29 AU AU2007326171A patent/AU2007326171B2/en active Active
- 2007-11-29 JP JP2009539185A patent/JP2010511381A/ja active Pending
- 2007-11-29 CA CA2669304A patent/CA2669304C/en active Active
- 2007-11-29 MX MX2009005496A patent/MX2009005496A/es active IP Right Grant
- 2007-11-29 WO PCT/KR2007/006084 patent/WO2008066330A1/en not_active Ceased
-
2013
- 2013-08-01 JP JP2013160426A patent/JP5871865B2/ja active Active
- 2013-08-19 US US13/970,074 patent/US9439931B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1302534A1 (en) * | 2000-06-26 | 2003-04-16 | Renomedix Institute Inc. | Cell fraction containing cells capable of differentiating into neural cells |
Non-Patent Citations (2)
| Title |
|---|
| JPN6012054594; Ｓｔｅｍ Ｃｅｌｌｓ，２００６-ＯＣＴ，２４（１０），ｐ．２２０９-１９ * |
| JPN6012054596; Ｂｌｏｏｄ，２００４，１０３（５），ｐ．１６６９-７５ * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018530992A (ja) * | 2015-07-22 | 2018-10-25 | 中國醫藥大學 | 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途 |
| US10660918B2 (en) | 2015-07-22 | 2020-05-26 | China Medical University | Method for enhancing insulin like growth factor 1 receptor expression of mesenchymal stem cell, method for isolating mesenchymal stem cell, and use of mesenchymal stem cell |
| US11110129B2 (en) | 2015-07-22 | 2021-09-07 | China Medical University | Method for treating multiple sclerosis |
| US11529373B2 (en) | 2015-07-22 | 2022-12-20 | China Medical University | Method for enhancing expression of insulin like growth factor 1 receptor in mesenchymal stem cell, method for obtaining mesenchymal stem cell, and method for treating brain tissue damage |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2099901A1 (en) | 2009-09-16 |
| CN101541954A (zh) | 2009-09-23 |
| EP2099901B1 (en) | 2015-09-09 |
| CA2669304A1 (en) | 2008-06-05 |
| AU2007326171B2 (en) | 2012-11-15 |
| US9387226B2 (en) | 2016-07-12 |
| MX2009005496A (es) | 2009-06-03 |
| US20100074875A1 (en) | 2010-03-25 |
| JP5871865B2 (ja) | 2016-03-01 |
| US9439931B2 (en) | 2016-09-13 |
| WO2008066330A1 (en) | 2008-06-05 |
| EP2099901A4 (en) | 2010-01-13 |
| WO2008066330A8 (en) | 2009-05-28 |
| CN101541954B (zh) | 2012-12-26 |
| US20130330306A1 (en) | 2013-12-12 |
| HK1134688A1 (en) | 2010-05-07 |
| JP2013226159A (ja) | 2013-11-07 |
| CA2669304C (en) | 2016-10-25 |
| AU2007326171A1 (en) | 2008-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5871865B2 (ja) | 神経前駆細胞又は神経幹細胞の神経細胞への分化及び増殖の誘導方法、分化及び増殖誘導用組成物、及び薬学的製剤 | |
| Zhao et al. | Intraspinal transplantation of CD34+ human umbilical cord blood cells after spinal cord hemisection injury improves functional recovery in adult rats | |
| JP7441079B2 (ja) | 神経変性を治療するための方法及び組成物 | |
| JP3976190B2 (ja) | 間葉系幹細胞を神経細胞に分化させる方法 | |
| ES2550456T3 (es) | Uso de una composición que contiene células madre mesenquimatosas derivadas de sangre de cordón umbilical humano para inducir diferenciación y proliferación de células precursoras neurales o células madre neurales a células neurales | |
| WO2018103406A1 (zh) | 一种治疗脑部损伤类疾病的神经干细胞注射液及其制备方法和使用方法 | |
| KR20090055691A (ko) | 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물 | |
| US7635591B2 (en) | Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease | |
| KR20070080561A (ko) | 중추 또는 말초 신경계 손상 치료용 조성물 | |
| EP2063902A1 (en) | Therapeutic cell medicine comprising skin tissue derived stem cell | |
| EP3508207B1 (en) | Cell preparations cultivated under low oxygen and sugar conditions, and their uses in therapy. | |
| CN111566204B (zh) | 培养细胞的制造方法、脊髓损伤疾病的治疗剂的制造方法 | |
| CN113388580B (zh) | 一种诱导脂肪干细胞分化为功能性多巴胺能神经元的方法及用途 | |
| TW201444973A (zh) | 用於治療神經退化的細胞療法 | |
| HK1134688B (en) | Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells | |
| WO2003060107A1 (en) | Separation, preparation and use of human embryo dorsal root ganglion (drg) stem cell | |
| KR20150062817A (ko) | 태반의 융모막 또는 와튼제대교질 유래 간엽줄기세포로부터 신경세포 및 유모세포를 분화시키는 방법 | |
| WO2010060928A2 (en) | Compositions for the treatment of ischemic tissue damage | |
| Mao et al. | Research Article Skin-Derived Precursor Cells Promote Angiogenesis and Stimulate Proliferation of Endogenous Neural Stem Cells after Cerebral Infarction | |
| JPWO2003018041A1 (ja) | 脊髄損傷の治療方法及びそのための治療剤 | |
| HK40028230A (en) | Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease | |
| HK1246145B (zh) | 用於治疗神经变性的细胞疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100825 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130123 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130123 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130123 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130801 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130808 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130913 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150402 |